265 related articles for article (PubMed ID: 16837072)
1. Coronaviruses and their therapy.
Haagmans BL; Osterhaus AD
Antiviral Res; 2006 Sep; 71(2-3):397-403. PubMed ID: 16837072
[TBL] [Abstract][Full Text] [Related]
2. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections.
Tong TR
Infect Disord Drug Targets; 2009 Apr; 9(2):223-45. PubMed ID: 19275708
[TBL] [Abstract][Full Text] [Related]
3. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
4. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.
de Wilde AH; Falzarano D; Zevenhoven-Dobbe JC; Beugeling C; Fett C; Martellaro C; Posthuma CC; Feldmann H; Perlman S; Snijder EJ
Virus Res; 2017 Jan; 228():7-13. PubMed ID: 27840112
[TBL] [Abstract][Full Text] [Related]
5. Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.
Tong TR
Expert Opin Ther Pat; 2009 Apr; 19(4):415-31. PubMed ID: 19441924
[TBL] [Abstract][Full Text] [Related]
6. Therapies for coronaviruses. Part I of II -- viral entry inhibitors.
Tong TR
Expert Opin Ther Pat; 2009 Mar; 19(3):357-67. PubMed ID: 19449500
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
8. Animal models for SARS and MERS coronaviruses.
Gretebeck LM; Subbarao K
Curr Opin Virol; 2015 Aug; 13():123-9. PubMed ID: 26184451
[TBL] [Abstract][Full Text] [Related]
9. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
11. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
12. Current status of anti-SARS agents.
Shigeta S; Yamase T
Antivir Chem Chemother; 2005; 16(1):23-31. PubMed ID: 15739619
[TBL] [Abstract][Full Text] [Related]
13. Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.
Wang Y; Grunewald M; Perlman S
Methods Mol Biol; 2020; 2203():1-29. PubMed ID: 32833200
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitors targeting coronavirus and filovirus entry.
Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
Strayer DR; Dickey R; Carter WA
Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SARS-CoV replication by siRNA.
Wu CJ; Huang HW; Liu CY; Hong CF; Chan YL
Antiviral Res; 2005 Jan; 65(1):45-8. PubMed ID: 15652970
[TBL] [Abstract][Full Text] [Related]
17. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
18. Human coronaviruses and therapeutic drug discovery.
Song LG; Xie QX; Lao HL; Lv ZY
Infect Dis Poverty; 2021 Mar; 10(1):28. PubMed ID: 33726861
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogues for the treatment of coronavirus infections.
Pruijssers AJ; Denison MR
Curr Opin Virol; 2019 Apr; 35():57-62. PubMed ID: 31125806
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
